EYPT - EyePoint Pharmaceuticals Inc Price to Sales

Corporate company logo of EyePoint Pharmaceuticals Inc (EYPT)

EyePoint Pharmaceuticals (EYPT) business is shielded from macroeconomic shocks due to stable demand for biotechnology. The current price-to-sales ratio demonstrates the market valuation of sales, where 10.70 determines the current magnitude of the metric. Revenues are based on the supply of sustained-release systems to ophthalmology centers. Growth is driven by the implementation of Durasert microimplants and the success of the EYP-1901 drug, which replaces frequent retinal injections.

EYPT EyePoint Corp Price-to-Revenue Ratio (07/04/2022 - 11/13/2026)

Analytical breakdowns for EyePoint Pharma (EYPT)

- current quotes and average value forecast:
Market Price eyepointpharma.com|EYPT - Consensus Target
- market capitalization statistics:
Market Value EyePoint Pharma|EYPT - Enterprise Value
- shareholders' equity book value data:
Net Asset Value per Share EyePoint Pharmaceuticals|EYPT - Company Book Value|Market Capitalization to Net Assets eyepointpharma.com|EYPT - Aggregate Company Assets
- debt obligations and liquidity statistics:
Debt to Capital EyePoint Pharmaceuticals|EYPT - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient EyePoint Corp|EYPT - Company Debts|Debt to Book Value Ratio EyePoint Pharma|EYPT - Company Long-Term Liabilities|Amount of Current Liabilities EyePoint Pharmaceuticals|Intermediate Coverage Ratio eyepointpharma.com
- earnings and multiples data:
EYPT - Company Net Income|Forward Earnings EyePoint Pharmaceuticals|EYPT - P/E Multiple|Future Price to Earnings Multiple EyePoint Pharmaceuticals Inc|EYPT - PEG Multiple|EV/EBITDA Multiple EyePoint Pharma|EYPT - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year EyePoint Pharmaceuticals|EYPT - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months eyepointpharma.com|EYPT - Earnings growth in current year|Earnings growth forecast for next year EyePoint Pharmaceuticals
- total revenue and sales volume data:
EYPT - Revenue and Sales Volume|Company Future Sales Volume eyepointpharma.com|EYPT - P/S Multiple|Market Cap to Future Revenue Ratio EyePoint Pharma
Fundamental company analysis:eyepointpharma.com (EYPT)
Mass-produced product of EyePoint Pharmaceuticals

For EyePoint Pharmaceuticals (EYPT), with its innovations in sustained-release drug delivery, the P/S ratio serves as an indicator of market confidence in its future dominance in ophthalmology. By analyzing the P/S time series, an investor can see the ratio of market capitalization to annual revenue, which makes it possible to identify asset overvaluation or the potential for capital growth relative to the business's actual cash flows.

Who EyePoint Pharmaceuticals competes with

ALC - Price to Sales|Bausch + Lomb - Market Cap to Revenue|Glaukos Corp (GKOS) - Price to Sales|Apellis Pharmaceuticals Inc - P/S Multiple|Price to Sales Belite Bio, Inc|Ocular Therapeutix (OCUL) - Price-to-Revenue Ratio|Price-to-Sales Ratio HROW (harrowinc.com)|Price-to-Revenue Ratio Viridian Therapeutics, Inc.|Price to Sales LENZ Therapeutics Inc LENZ|P/S Multiple OCS|Price-to-Revenue Coefficient Kodiak Corp|Price-to-Revenue Ratio Aldeyra Therapeutics, Inc. ALDX|KALA: Market Cap to Revenue Ratio|IRD: Market Cap to Revenue|OKYO Pharma Limited - Market Cap to Sales Volume|ADVM (adverum.com) - Market Cap to Revenue|Outlook Therapeutics Corp - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Clearside Biomedical|NovaBay - Price-to-Sales Ratio|P/S Multiple KPRX|ALIM (alimerasciences.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple EYEN (Eyenovia)|P/S Multiple Guardion Health GHSI|OCUP - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio OPT (opthea.com)